Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.57 |
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | CASP3 | P42574 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749111 | 1.00 | KMT2A (0.62) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL19951678 | 1.00 | KMT2A (0.62) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL7461050 | 0.96 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL30749158 | 0.95 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL12466711 | 0.95 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL14997839 | 0.93 | KMT2A (0.58) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29354378 | 0.93 | KMT2A (0.58) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29908078 | 0.93 | KMT2A (0.58) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL30338216 | 0.93 | KMT2A (0.58) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29400089 | 0.93 | KMT2A (0.58) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |